A PHASE I DOSE ESCALATION AND EXPANSION STUDY OF INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：1

作者：

Eigentler, Thomas ^{[1
]}

Heinzerling, Lucie ^{[2
]}

Krauss, Juergen ^{[3
]}

Weishaupt, Carsten ^{[4
]}

Mohr, Peter ^{[5
]}

Ochsenreither, Sebastian ^{[6
]}

Terheyden, Patrick ^{[7
]}

Martin-Liberal, Juan ^{[8
]}

Oliva, Marc ^{[8
]}

Lebbe, Celeste ^{[9
]}

Fluck, Michael ^{[10
]}

Brossart, Peter ^{[11
]}

Trigo Perez, Jose Manuel ^{[12
]}

Bauernfeind, Franz-Georg ^{[11
]}

Kays, Sarah-Katharina ^{[13
]}

Seibel, Tobias ^{[13
]}

Schoenborn-Kellenberger, Oliver ^{[13
]}

Stosnach, Claudia ^{[13
]}

Daehling, Angelika ^{[13
]}

Schmitt-Bormann, Beate ^{[13
]}

Gnad-Vogt, Ulrike ^{[13
]}

机构：

[1] Univ Med Ctr Tubingen, Tubingen, Germany

[2] Univ Erlangen Nurnberg, Erlangen, Germany

[3] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[4] Univ Munster, Munster, Germany

[5] Elbe Med Ctr, Buxtehude, Germany

[6] Charite Campus Benjamin Franklin, Berlin, Germany

[7] Univ Lubeck, Lubeck, Germany

[8] Hosp Duran & Reynals, Barcelona, Spain

[9] Hop St Louis, Paris, France

[10] Fachklin Hornheide, Munster, Germany

[11] Univ Clin Bonn, Bonn, Germany

[12] Hosp Clin V de la Victoria, Malaga, Spain

[13] CureVac AG, Tubingen, Germany

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷

关键词：

D O I：

10.1136/jitc-2020-SITC2020.0800

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

800

引用

页码：A478 / A479

页数：2

共 50 条

[21] A phase 1/1b dose escalation study of iniparib as a single agent and in combination with gemcitabine/carboplatin in patients with advanced solid tumors
Mita, Monica
Baffa, Raffaele
Charpentier, Eric
Lockhart, Craig A.
Morris, John C.
Rixe, Olivier
Sarantopoulos, John
Ramanathan, Ramesh
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
[22] Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors.
Zhou, Cai
He, Yayi
Ren, Shengxiang
Li, Wei
Zhu, Jun
Yu, Jia
Wang, Lei
Xiong, Anwen
Xu, Nong
Mao, Chenyu
Pan, Beiqing
Liu, Ying
Zhou, Hui
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[23] Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies
Salgia, Ravi
Patel, Premal
Bothos, John
Yu, Wei
Eppler, Steve
Hegde, Priti
Bai, Shuang
Kaur, Surinder
Nijem, Ihsan
Catenacci, Daniel V. T.
Peterson, Amy
Ratain, Mark J.
Polite, Blase
Mehnert, Janice M.
Moss, Rebecca A.
CLINICAL CANCER RESEARCH, 2014, 20 (06) : 1666 - 1675
[24] Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial
Patnaik, Amita
Weiss, Glen J.
Rasco, Drew W.
Blaydorn, Lisa
Mirabella, Amy
Beeram, Murali
Guo, Wei
Lu, Sharon
Danaee, Hadi
McEachern, Kristen
Im, Ellie
Sachdev, Jasgit C.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (01) : 93 - 103
[25] Single-Agent Tislelizumab, an Anti-PD-1 Antibody: Results from a Phase 1 Expansion Cohort in NSCLC Patients
Barlow, P.
Jameson, M.
Lin, C.
Wu, J.
Pirzkall, A.
Lee, J.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S721 - S721
[26] A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
Harding, James J.
Telli, Melinda
Munster, Pamela
Voss, Martin H.
Infante, Jeffrey R.
DeMichele, Angela
Dunphy, Mark
Le, Mai H.
Molineaux, Chris
Orford, Keith
Parlati, Frank
Whiting, Sam H.
Bennett, Mark K.
Tannir, Nizar M.
Meric-Bernstam, Funda
CLINICAL CANCER RESEARCH, 2021, 27 (18) : 4994 - 5003
[27] A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma
Gong, Jifang
Guo, Ye
Zhang, Yanqiao
Ba, Yi
Chen, Tong
Li, Wei
Zhou, Caicun
Wang, Mengzhao
Yang, Haiyan
Zhou, Yuhong
Cai, Qiqing
Wang, Ziping
Huang, Gang
Zhang, Wei
Su, Rila
Cai, Zhongheng
Yue, Zenglian
Dou, Jinzhou
Li, Peiqi
Wu, Rachel
Tse, Archie N.
Shen, Lin
TARGETED ONCOLOGY, 2024, 19 (05) : 723 - 733
[28] A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
Naing, Aung
Gainor, Justin F.
Gelderblom, Hans
Forde, Patrick M.
Butler, Marcus O.
Lin, Chia-Chi
Sharma, Sunil
de Olza, Maria Ochoa
Varga, Andrea
Taylor, Matthew
Schellens, Jan H. M.
Wu, Hongqian
Sun, Haiying
Silva, Antonio P.
Faris, Jason
Mataraza, Jennifer
Cameron, Scott
Bauer, Todd M.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
[29] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
Robert, Francisco
Sandler, Alan
Schiller, Joan H.
Liu, Glenn
Harper, Karen
Verkh, Lev
Huang, Xin
Ilagan, Jennifer
Tye, Lesley
Chao, Richard
Traynor, Anne M.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (04) : 669 - 680
[30] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
Francisco Robert
Alan Sandler
Joan H. Schiller
Glenn Liu
Karen Harper
Lev Verkh
Xin Huang
Jennifer Ilagan
Lesley Tye
Richard Chao
Anne M. Traynor
Cancer Chemotherapy and Pharmacology, 2010, 66 : 669 - 680

← 1 2 3 4 5 →